证券代码： 600538 证券简称： 国发股份 公告编号：临 2023-048 北海国发川山生物股份有限公司 第十一届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北海国发川山生物股份有限公司（以下简称"公司"）于 2023 年 12 月 15 日以电话及邮件方式发出了关于召开公司第十一届董事会第四次会议的通知， 本次会议于 2023 年 12 月 20 日以通讯表决方式召开，会议应参加表决董事 9 人， 实际参加表决董事 9 人。会议的召集、召开和表决符合《公司法》及《公司章 程》的有关规定，会议召开合法有效。 二、董事会会议审议情况 1、审议通过《关于修订<公司章程>的议案》 表决结果：同意【9】票，反对【0】票，弃权【0】票，赞成票占董事会有 效表决权的【100】%。 《公司章程》内容详见上海证券交易所网站（http://www.sse.com.cn）。 2、审议通过《关于修订<股东大会议事规则>的议案》 表决结果：同意【9】票，反对【0】票，弃权【0】票，赞成票占董事 ...

北海国发川山生物股份有限公司 第四条 公司董事会办公室负责审计委员会日常的工作联络、会议组织、材料准备、 档案管理等工作。审计委员会履行职责时，公司管理层及相关部门须给予配合。 第二章 审计委员会的人员组成 第五条 审计委员会成员应当由不在公司担任高级管理人员的董事担任。公司审计 委员会由三名董事组成，其中两名为独立董事。审计委员会委员由董事会选举产生。 第六条 审计委员会全部成员均须具有能够胜任审计委员会工作职责的专业知识和 经验。 董事会审计委员会工作细则 （2023 年修订） 第一章 总则 第一条 为了提高北海国发川山生物股份有限公司（以下简称"公司"）公司治理水 平,规范公司董事会审计委员会的运作，根据《中华人民共和国公司法》《中华人民共和 国证券法》《上市公司独立董事管理办法》《上海证券交易所股票上市规则》《上市公司治 理准则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等相关规范性文 件及《北海国发川山生物股份有限公司章程》（以下简称"《公司章程》"）的规定，制定 本工作细则。 第二条 审计委员会是董事会下设的专门委员会，对董事会负责，向董事会报告工 作。 第三条 审计委员会成员须 ...

●北海国发川山生物股份有限公司（以下简称"公司"）控股股东朱蓉娟及 其一致行动人彭韬收到海南省海口市美兰区人民法院下达的《执行裁定书》，裁 定变价朱蓉娟持有的公司 2,910 万股股份。 ●本次股份被司法处置，将导致控股股东持有公司股份的比例下降，但不会 对公司控制权及公司的正常生产经营产生重大不利影响。 2023 年 11 月 15 日，公司接到控股股东朱蓉娟的通知，其收到海南省海 口市美兰区人民法院《执行裁定书》，现将具体情况披露如下： 一、执行案件的基本情况 （一）执行裁定书的主要内容 近日，海南省海口市美兰区人民法院向朱蓉娟、彭韬下达了 《执行裁定书》 (2023)琼 0108 执 6602 号之一，裁定如下： 证券代码：600538 证券简称：国发股份 公告编号：临 2023-047 北海国发川山生物股份有限公司 关于控股股东收到《执行裁定书》暨部分股份 将被变价处理的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 变价被执行人朱蓉娟持有的公司 2,910 万股股票。 本裁定书送达后即发生法 ...

北海国发川山生物股份有限公司 投资者关系活动记录表 证券简称：国发股份 证券代码：600538 编号：2023-001 R特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 R现场参观 £电话会议 □ 其他 投资者关系活动情况如下： 时间：2023年11月10日 参与机构及人员： 时间及参与单位名称 融邦投资：阮学林、詹明皓、阮海龙； ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥89,013,382.17, a decrease of 25.30% compared to the same period last year[4]. - The net profit attributable to shareholders for Q3 2023 was -¥5,976,006.97, representing a decline of 124.77% year-on-year[4]. - The basic earnings per share for Q3 2023 was -¥0.01, a decrease of 120.00% compared to the same period last year[4]. - The weighted average return on equity for Q3 2023 was -0.64%, a decline of 124.90% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was -¥6,179,663.42, down 125.66% year-on-year[4]. - Total operating revenue for the first three quarters of 2023 was CNY 283,265,700.12, a decrease of 16.3% compared to CNY 338,428,175.18 in the same period of 2022[20]. - The net loss for the first three quarters of 2023 was CNY 14,325,113.35, compared to a net profit of CNY 34,258,280.90 in the same period of 2022[21]. - The company's operating profit for the first three quarters of 2023 was a loss of CNY 13,483,108.36, contrasting with an operating profit of CNY 39,664,488.62 in the previous year[20]. - The basic and diluted earnings per share for the first three quarters of 2023 were both CNY -0.03, compared to CNY 0.06 in the same period of 2022[21]. Cash Flow - The cash flow from operating activities for the year-to-date period was -¥18,709,066.34, indicating a significant cash outflow[4]. - The net cash flow from operating activities was -CNY 18,709,066.34, an improvement from -CNY 41,474,329.81 year-over-year[23]. - The cash inflow from operating activities was CNY 300,206,440.60, a decrease of 1.1% compared to CNY 305,263,487.66 in the same period of 2022[23]. - The cash outflow for purchasing goods and services was CNY 220,188,765.71, down 15.9% from CNY 261,787,797.96 in the previous year[23]. - The cash paid for fixed assets and other long-term assets was CNY 7,029,050.24, an increase of 104.5% compared to CNY 3,431,180.38 in the previous year[24]. - The cash received from investment recoveries was CNY 10,000,000.00, marking a new source of cash inflow[24]. - The cash inflow from financing activities was CNY 500,000.00, compared to CNY 5,350,642.30 in the previous year, indicating a significant decrease[24]. - The net cash flow from financing activities was -CNY 1,518,985.93, a decline from CNY 3,863,177.53 year-over-year[24]. - The ending cash and cash equivalents balance was CNY 131,784,881.69, down from CNY 142,872,555.16 at the end of the same period last year[24]. Assets and Liabilities - The total assets at the end of Q3 2023 were ¥1,112,807,351.42, down 2.57% from the end of the previous year[5]. - As of September 30, 2023, the company's total current assets amounted to ¥530,685,864.68, a decrease of 2.6% from ¥543,260,916.19 at the end of 2022[17]. - The total equity attributable to shareholders at the end of Q3 2023 was ¥935,837,067.16, a decrease of 1.65% from the previous year-end[5]. - The total liabilities as of the end of the third quarter of 2023 were CNY 166,652,954.64, down from CNY 182,165,382.12 at the end of 2022[19]. - The company's long-term equity investments decreased to ¥94,359,381.82 from ¥107,817,382.45, representing a decline of approximately 12.5%[17]. - The company's cash and cash equivalents decreased to ¥151,202,833.23 from ¥170,858,268.06, reflecting a decline of approximately 11.5%[17]. - Accounts receivable increased to ¥242,685,221.33, up from ¥223,539,862.24, indicating a growth of about 8.6%[17]. - The company's inventory increased to ¥91,661,162.65 from ¥84,921,944.31, reflecting a growth of approximately 7.5%[17]. - The total amount of other receivables rose to ¥5,353,074.02 from ¥2,714,880.25, marking an increase of about 97.5%[17]. Shareholder Information - The company’s major shareholder, Zhu Rongjuan, holds 17.25% of shares, with 90,400,542 shares frozen and 67,440,000 shares pledged[12]. - The company is currently implementing a share reduction plan by director Wu Peicheng, aiming to reduce up to 1,051,300 shares by January 1, 2024[14]. - The company’s major shareholders include several individuals and entities, with a combined holding of 3.25% by related parties[12]. Investment Income - The company reported a significant decrease in investment income due to a decline in the value of its holdings in the Huada Gongying No. 1 Fund[8]. - The company experienced a decline in investment income, reporting a loss of CNY 14,055,160.37 compared to a gain of CNY 12,522,875.38 in the previous year[20]. - The company completed the transfer of 1% equity in Youfeng Biotechnology for ¥13.2 million, expected to increase current earnings by approximately ¥3.2 million after registration[13].

证券代码：600538 证券简称：国发股份 公告编号：临 2023-046 北海国发川山生物股份有限公司 关于控股股东的一致行动人股份被司法冻结的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北海国发川山生物股份有限公司（以下简称"公司"）近日通过中国证券 登记结算有限公司上海分公司的 PROP 系统查询得知公司控股股东的一致行动 人广西国发投资集团有限公司（以下简称"国发集团"）持有的公司 17.94 万 股股份于 2023 年 9 月 20 日被南宁市江南区人民法院司法冻结。现将相关事项 公告如下： 公司在得知上述司法冻结后，立即通知国发集团，要求其积极与相关法院 进行联系，核实确定上述司法冻结的申请人、具体案由、涉诉金额等信息。后 续公司又反复多次致电进行催促，但截至目前，公司尚未收到相关资料。 二、控股股东股份累计被冻结/标记的情况 截至 2023 年 9 月 22 日，控股股东及一致行动人股份累计被司法冻结情况 1 如下： 单位：股 股东 持股数量 持股比 例 累计被司法冻 结、司法标记及 轮候冻结数量 ...

公司对投资者在本次业绩说明会上提出的普遍关心的问题给予了回复，现将 主要问题及回复整理如下： 证券代码：600538 证券简称：国发股份 公告编号：临 2023-045 北海国发川山生物股份有限公司 关于 2023 年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北海国发川山生物股份有限公司（以下简称"公司"）于 2023 年 9 月 22 日 下 午 13:00-14:00 通过上海证券交易所上证路演中心平台 （http://roadshow.sseinfo.com/，以下简称"上证路演中心"）以网络互动 的方式召开了 2023 年半年度业绩说明会，现将业绩说明会召开情况公告如下： 一、2023 年半年度业绩说明会召开基本情况 2023 年 9 月 6 日，公司在上海证券交易所网站（www.sse.com.cn）及指定 信息披露媒体披露了《关于召开 2023 年半年度业绩说明会的公告》。 2023 年 9 月 22 日 13:00-14:00，公司董事长、总裁潘利斌先生，董事、副 总裁、财务 ...

证券代码：600538 证券简称：国发股份 公告编号：临 2023-044 北海国发川山生物股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 会议召开时间：2023 年 9 月 22 日（星期五）下午 13:00-14:00 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年上半年的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 9 月 22 日下午 13:00-14:00 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 9 月 15 日（星期五 ...

Financial Performance - The company's operating revenue for the first half of 2023 was approximately ¥194.25 million, a decrease of 11.41% compared to ¥219.26 million in the same period last year[18]. - The net profit attributable to shareholders of the listed company was a loss of approximately ¥9.75 million, representing a decline of 211.81% from a profit of ¥8.72 million in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of approximately ¥10.54 million, a decrease of 236.00% compared to a profit of ¥7.75 million last year[18]. - The net cash flow from operating activities was approximately -¥26.08 million, slightly improved from -¥27.22 million in the previous year[18]. - Basic earnings per share for the first half of 2023 were -¥0.02, a decline of 200.00% from ¥0.02 in the same period last year[19]. - The weighted average return on net assets was -1.03%, a decrease of 1.98 percentage points compared to 0.95% in the previous year[19]. - The decline in revenue and net profit was primarily due to a 22.5% decrease in revenue and a 64.8% decrease in net profit from the subsidiary, Gaoseng Biological[20]. - The investment income from the Huada Gongying No. 1 Fund decreased by ¥6.72 million due to the decline in stock prices of its listed projects[20]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥1.13 billion, down 1.45% from ¥1.14 billion at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company were approximately ¥941.81 million, a decrease of 1.02% from ¥951.56 million at the end of the previous year[18]. - The company's total equity as of June 30, 2023, was CNY 952,029,006.63, down from CNY 959,979,510.13, a decrease of about 0.8%[116]. - Total liabilities decreased to CNY 173,566,808.01 from CNY 182,165,382.12, reflecting a reduction of approximately 4.4%[116]. Operational Overview - The company operates in the wholesale industry, specifically in pharmaceutical manufacturing and distribution, molecular diagnostics, and remote medical services[23][24]. - The pharmaceutical manufacturing segment includes products such as "Haibao" pearl eye drops and various traditional Chinese medicine products[26]. - The company has 8 direct stores, 55 franchise stores, and 3 licensed franchise stores in the Guangxi region[29]. - The molecular diagnostics subsidiary focuses on DNA testing solutions, providing equipment and technical services across the DNA testing industry[30]. - The company collaborates with medical institutions to establish imaging and radiation therapy centers, sharing investment and revenue[31][32]. Market Trends and Industry Insights - In the first half of 2023, the pharmaceutical manufacturing industry in China achieved a main business income of CNY 1,249.6 billion, a decrease of 2.9% year-on-year[34]. - The total profit of the pharmaceutical manufacturing industry was CNY 179.45 billion, down 17.1% compared to the same period last year[34]. - The overall growth rate of the pharmaceutical distribution industry is projected to decline in 2023, with an expected market size exceeding CNY 4 trillion by 2028, based on a compound annual growth rate of 7%[35]. - The digital healthcare market is anticipated to grow from USD 211 billion in 2022 to USD 809.2 billion by 2030, reflecting an annual compound growth rate of 18.6%[39]. Regulatory and Compliance Issues - The Chinese government has initiated measures to combat fraud in the medical insurance sector, enhancing regulatory oversight and accountability[40]. - The implementation of the "Two Invoice System" is accelerating the concentration of the pharmaceutical distribution industry, leading to increased competition and market consolidation[35]. - The company faces increasing operational pressure due to intensified market competition and regulatory changes in the pharmaceutical industry[44]. Environmental Responsibility - The total wastewater discharge in the first half of 2023 was 4,295 tons, with chemical oxygen demand emissions of 111.67 kg and biochemical oxygen demand emissions of 26.20 kg[76][77]. - The company’s wastewater treatment facility has a capacity of 240 tons per day, utilizing a pre-treatment, biochemical treatment, and advanced treatment process[77]. - The company reported no hazardous waste generated in the first half of 2023, indicating effective waste management practices[77]. - The company’s commitment to environmental responsibility includes adherence to pollution discharge standards and regular maintenance of wastewater treatment facilities[76][78]. Shareholder and Governance Matters - The company appointed Mr. Pan Libin as the chairman of the 11th board of directors and Mr. Lü Qiujun as the chairman of the 11th supervisory board during the annual general meeting held on May 22, 2023[71][72]. - The controlling shareholder Zhu Rongjuan holds 90,400,542 shares, representing 17.25% of the total shares, all of which are subject to judicial freezing[88]. - The company has not disclosed any new employee incentive plans or stock ownership plans during the reporting period[75][78]. - The company has established commitments to resolve competition issues with controlling shareholders[83]. Financial Reporting and Accounting Practices - The financial statements are prepared based on the principle of continuous operation, reflecting the company's financial status and operating results accurately[146]. - The company adheres to the relevant enterprise accounting standards, ensuring the financial reports are true and complete[146]. - The company recognizes financial assets when it becomes a party to the financial instrument contract, measuring them initially at fair value[159]. - The company applies expected credit loss model for impairment measurement of financial instruments, considering the risk of default[161]. Future Plans and Projections - The company plans to enhance its product pipeline by increasing R&D efforts for forensic identification kits and expanding its market presence through quality distributor recruitment[50]. - The company aims to diversify its business by expanding into new detection and identification areas such as drug control and environmental testing[50]. - The company has set a performance guidance for the next half of the year, projecting a revenue growth of 10% to 15% compared to the first half of 2023[136].

证券代码：600538 证券简称：国发股份 公告编号：临 2023-043 北海国发川山生物股份有限公司 关于控股股东持有公司的股份被司法轮候冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北海国发川山生物股份有限公司（以下简称"公司"）于 2023 年 8 月 18 日 收到控股股东朱蓉娟女士的相关通知，其持有的公司 2,910 万股股份于 2023 年 8 月 16 日被海南省海口市美兰区人民法院司法轮候冻结。现将相关事项公告如 下： 司法冻结的具体情况 2022 年 7 月 25 日，朱蓉娟女士将持有的公司 2,910 万股股份质押给海南润 泰欣茂小额贷款有限公司，为海南风正顺农业科技有限公司向海南润泰欣茂小额 贷款有限公司的 5,000 万元人民币借款提供担保，其配偶彭韬先生（公司董事） 亦为本笔借款提供了担保。具体详见公司于 2022 年 7 月 27 日在《上海证券报》 《中国证券报》《证券时报》《证券日报》和上海证券交易所网站 （www.sse.com.cn） 披露的《关于控股股东部分股份解除质押及再 ...